Sickle Cell Trait (SCT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Sickle Cell Trait (SCT) Market Outlook

Thelansis’s “Sickle Cell Trait (SCT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sickle Cell Trait (SCT) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Sickle Cell Trait (SCT) Overview

The sickle cell trait represents a hereditary hematological anomaly characterized by a single abnormal allele of the hemoglobin beta gene. This contrasts with sickle cell disease, where both alleles are abnormal. Individuals with sickle cell trait typically exhibit no symptomatic manifestations related to sickling and thus generally experience an improved quality of life compared to sickle cell disease patients. Notably, individuals possessing the sickle cell trait do not demonstrate an elevated mortality risk relative to the general populace. This discourse delves into the assessment and treatment of sickle cell trait, emphasizing the collaborative efforts of the interdisciplinary team in enhancing the care provided to affected individuals. The genetic basis of the sickle cell trait is rooted in an atypical hemoglobin variant termed sickle hemoglobin (Hb S), resulting from a point mutation in the beta-globin chain. This genetic alteration entails a nucleotide substitution where thymine replaces adenine at codon 6 of the beta hemoglobin chain. This substitution subsequently prompts the amino acid sequence conversion from glutamic acid to valine. This valine-based hemoglobin variant renders red blood cells susceptible to assuming a sickle shape under reduced oxygen levels. Individuals harboring sickle cell trait inherit one Hb S allele from one parent and one normal HbA allele from the other, conferring a heterozygous genetic makeup. It is generally not associated with frequent vaso-occlusive crises, a characteristic feature of sickle cell disease. However, individuals with sickle cell trait may exhibit analogous clinical presentations to sickle cell anemia if exposed to circumstances conducive to sickling. Such conditions encompass profound hypoxia, dehydration, heightened sympathetic activity, temperature extremes, elevated 2,3-diphosphoglycerate (2,3-DPG) levels, and immune cell release. The presence of Hb S precipitates the occlusion of minute capillaries, particularly within the osseous structures, by sickled erythrocytes. Concurrently, other cellular elements, including inflammatory cells and platelets, contribute to escalated adhesion of the sickled red blood cells. This pathological process can potentially unfold across multiple organ systems, encompassing the thoracic region, cardiac structures, pulmonary tissue, abdominal organs, kidneys, and peripheral extremities. Cumulative ischemic events stemming from these occurrences may lead to chronic organ damage. Sickle cell trait exhibits a higher prevalence within specific ethnic groups, such as:

• African Americans (with approximately 8 to 10 percent carrying the sickle cell trait)
• Hispanics
• South Asians
• Caucasians hailing from southern Europe
• Individuals originating from Middle Eastern nations

Differential diagnostic considerations for sickle cell trait encompass various forms of sickle cell disease, beta-thalassemia major, and beta-thalassemia minor. While sickle cell trait has been associated with various complications, including papillary necrosis, asymptomatic bacteriuria, splenic infarction, and exercise-induced fatality, the prognosis for individuals with sickle cell trait is generally favorable. It is pertinent to acknowledge that sickle cell trait is an inheritable hematologic anomaly affecting many Americans, with estimates ranging from one to three million individuals.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Sickle Cell Trait (SCT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034